Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Authors:
- 30 April 2013
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (11) , 2385-2391
Abstract
Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certain types of B cell malignancies. Early stage clinical trials found ibrutinib to be particularly active in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), providing the rationale for ongoing phase 3 trials. In contrast to conventional chemo-immunotherapy, ibrutinib is not myelosuppressive, and responses are not affected by disease features that predict failure to respond to or short remission durations after chemo-immunotherapy, such as del17p. In CLL, ibrutinib characteristically causes an early redistribution of tissue-resident CLL cells into the blood, with rapid resolution of enlarged lymph nodes, along with a surge in lymphocytosis. Later, after weeks to months of continuous ibrutinib therapy, the growth- and survival-inhibitory activities of ibrutinib result in the normalization of lymphocyte counts and remissions in a majority of patients. This review discusses the discovery, preclinical and clinical development of ibrutinib, its pathophysiological basis, and outlines perspectives for future use of ibrutinib.Keywords
This publication has 53 references indexed in Scilit:
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Primary B Cell Immunodeficiencies: Comparisons and ContrastsAnnual Review of Immunology, 2009
- Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and HomingImmunity, 2007
- Roles for phosphoinositide 3‐kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homingEuropean Journal of Immunology, 2006
- The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2Journal of Experimental Medicine, 2003
- The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspectiveImmunological Reviews, 2000
- Expression of Bruton's tyrosine kinase protein within the B cell lineageEuropean Journal of Immunology, 1994
- Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID MiceScience, 1993
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993
- The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature, 1993